BIOCOCKTAIL对乳腺癌细胞MDA-MB-231凋亡的促进作用

目的从细胞凋亡方面观察BIOCOCKTAIL（益生菌微生物制剂）对乳腺癌细胞MDA-MB-231的抑制作用。方法采用FITC和PI双染色法及TUNEL法检测凋亡。结果通过FITC和PI双染色法,观察到BIOCOCKTAIL可显著增加乳腺癌细胞MDA-MB一231凋亡细胞。I组乳腺癌细胞系（8．1％绑38．7％,P〈0．05）,Ⅱ组乳腺癌细胞系（6．9％掷19．4％,P〈0．05）。TUNEL法检测MDA-MB-231细胞凋亡现象明显增多。结论BIOCOCKTAIL能够有效诱导乳腺癌细胞MDA-MB-231凋亡,有可能成为乳腺癌治疗的补充方案。     

鞘氨醇激酶1参与依托泊苷抑制人乳腺癌MDA-MB-231细胞增殖、迁移的研究

目的利用抑制乳腺癌MDA-MB-231细胞中SK-1基因表达,结合依托泊苷对细胞增殖的影响,研究乳腺癌的治疗新方法。方法将依托泊苷分别处理野生型及SK-1敲除型MDA-MB-231细胞,^3H-TdR掺入法分析细胞增殖,Transwell法分析细胞迁移,Western印迹检测SK-1蛋白表达及细胞周期检验点相关信号因子的蛋白表达,RT-PCR检测细胞内SK-1的mRNA表达量。结果依托泊苷在较高剂量时,MDA-MB-231细胞存活率明显下降,但依托泊苷却呈浓度依赖性促进乳腺癌细胞SK-1 mRNA及蛋白水平表达,将SK-1敲除,细胞迁移率下降,而且可以增强G1期各抑癌基因的激活或高表达,使细胞周期阻滞。结论SK-1基因敲除有效增强肿瘤细胞对化疗药物的敏感性。     

沉默CXCL1基因抑制三阴性乳腺癌细胞MDA-MB-231的迁移、侵袭的研究

为探讨CXCL1基因对三阴性乳腺癌细胞MDA-MB-231的迁移、侵袭作用的影响,该研究设计针对CXCL1基因的小干扰RNA,用实时荧光定量PCR和酶联免疫吸附测定试验分别在RNA和蛋白质水平上检测干扰效率;采用流式细胞术学技术检测细胞的周期和凋亡情况;采用transwell迁移和侵袭试验分别检测细胞的迁移及侵袭能力。结果显示,与siRNA-NC组细胞相比,siCXCL1-1、siCXCL1-2、siCXCL1-3细胞中CXCL1基因的mRNA和蛋白表达均下调,且si CXCL1-3干扰效率最高,mRNA及蛋白表达水平分别降低了75%(p<0.01)和46%(p<0.01)。细胞凋亡试验和细胞周期试验结果显示,沉默CXCL1基因后对三阴性乳腺癌细胞系MDA-MB-231细胞的凋亡和周期无明显影响,差异无统计学意义(p>0.05)。transwell小室迁移和侵袭试验显示,沉默CXCL1基因能够显著抑制三阴性乳腺癌细胞MDA-MB-231的迁移和侵袭能力(p<0.01)。研究成果为临床乳腺癌中以CXCL1基因为靶点的分子治疗提供了理论依据。     

迷迭香酸对乳腺癌MDA-MB-231细胞增殖、凋亡和迁移能力的影响

研究迷迭香酸对乳腺癌MDA-MB-231细胞增殖、凋亡和迁移能力的影响。采用磺酰罗丹明B(SRB)法测定迷迭香酸对乳腺癌MDA-MB-231细胞增殖的影响,Hoechst 33258荧光染色法观察细胞凋亡形态,Annexin VFITC/PI检测细胞凋亡率;同时,细胞划痕实验检测迷迭香酸对MDA-MB-231细胞体外迁移能力的影响,实时荧光PCR(qPCR)法检测Bax、Bcl-2、Caspase-3、MMP-2和MMP-9基因的表达水平。研究结果显示迷迭香酸能抑制乳腺癌MDA-MB-231细胞的增殖,且呈时间剂量依赖性;迷迭香酸处理后的MDA-MB-231细胞出现明显的凋亡形态,且细胞凋亡率明显增加,Bax和caspase-3 mRNA表达水平增加,而Bcl-2 mRNA表达水平降低。另外,迷迭香酸作用后可剂量依赖性地降低MDA-MB-231细胞的体外迁移能力;同时降低MMP-2和MMP-9 mRNA的表达。因此,迷迭香酸能有效的抑制MDA-MB-231细胞的增殖,诱导细胞凋亡,降低细胞迁移能力。     

沉默FBI-1基因对三阴性乳腺癌细胞MDA-MB-231增殖和凋亡的影响

本研究旨在观察短发夹状RNA (short hairpin RNA, shRNA)介导的人类免疫缺陷病毒短转录诱导物连接因子1 (FBI-1)基因沉默对三阴性乳腺癌细胞MDA-MB-231增殖和凋亡的影响。用qRT-PCR和Western blot分别检测FBI-1、Bcl-2、Bax、cleaved-Caspase3和Survivin的mRNA和/或蛋白的表达水平;采用shRNA干扰技术沉默MDA-MB-231细胞中FBI-1基因的表达;用CCK-8法以及克隆形成实验检测细胞增殖;用流式细胞术检测细胞凋亡;用裸鼠皮下成瘤实验检测细胞的成瘤能力。结果显示,MDA-MB-231细胞的FBI-1 mRNA和蛋白的表达水平明显高于正常乳腺上皮细胞MCF-10A;经shRNA靶向沉默FBI-1基因表达后,细胞增殖能力明显降低,细胞凋亡率显著增高,伴随Bcl-2和Survivin蛋白表达明显下调、Bax蛋白表达显著上调和Caspase 3活化,MDA-MB-231细胞的裸鼠皮下成瘤能力受抑制。以上结果提示,靶向沉默FBI-1基因表达可以抑制MDA-MB-231细胞增殖,诱导细胞凋亡并抑制细胞的裸鼠皮下成瘤能力。     

乳腺癌微环境中脂肪细胞可通过瘦素促进乳腺癌MDA-MB-231细胞的增殖与迁移

为研究乳腺癌微环境中前脂肪细胞和成熟脂肪细胞对乳腺癌MDA-MB-231细胞增殖和迁移能力的影响,该研究将前脂肪细胞3T3-L1诱导为成熟脂肪细胞,再将前脂肪细胞和成熟脂肪细胞分别与乳腺癌MDA-MB-231细胞共培养,通过显微镜成像、油红O染色实验、MTT实验、Transwell实验分别观察肿瘤细胞形态、增殖及迁移能力的改变。Western blot和ELISA检测前脂肪细胞和成熟脂肪细胞瘦素(leptin)的表达水平。细胞免疫荧光法和Western blot分别检测肿瘤细胞中瘦素受体(leptin recepter,Ob-R)、瘦素信号通路关键分子及下游靶因子的表达水平变化。结果显示,共培养后,肿瘤细胞形态变得更加纤长,增殖能力增加(P0.05),穿过小室的细胞数明显增多(P0.05)。在成熟脂肪细胞共培养组的肿瘤细胞中还出现了明显的脂质累积。Western blot和ELISA检测发现,前脂肪细胞和成熟脂肪细胞均有瘦素的表达。与空白对照组相比,两个共培养组中肿瘤细胞的p-Akt、p-STAT3、cyclin D1和MMP9蛋白质水平均明显上调(P0.05),而p-ERK1/2仅在前脂肪细胞共培养组中上调(P0.001),在成熟脂肪细胞共培养组中没有明显变化。和共培养组相比,瘦素中和抗体处理后可以抑制肿瘤细胞中瘦素下游信号通路的激活。该研究表明,前脂肪细胞和成熟脂肪细胞均能促进乳腺癌MDA-MB-231细胞的增殖和迁移,且这一促进作用和瘦素信号通路有关。     

MicroRNA-221/222对乳腺癌MDA-MB-231/DOX细胞阿霉素耐药性的影响

目的:探讨微小RNA-221/222(miR-221/222)对乳腺癌MDA-MB-231/阿霉素(DOX)细胞DOX耐药性的影响。方法:采用脂质体法转染miR-221/222抑制物(miR-221/222 inhibitor)至MDA-MB-231/DOX细胞内(Inhibitor组),同时设立空白对照组和转染无关序列的阴性对照组,采用实时荧光定量PCR (qRT-PCR)检测MDA-MB-231细胞株及MDA-MB-231/DOX细胞株的miR-221/222表达水平及转染效率;CCK-8法检测转染48 h后MDA-MB-231/DOX细胞对DOX药物敏感性的变化;流式细胞术(FCM)检测转染MDA-MB-231/DOX细胞的细胞凋亡率;蛋白免疫印迹实验(WB)检测转染后MDA-MB-231/DOX细胞内促凋亡蛋白p53上调凋亡调控因子(PUMA),Bcl2蛋白修饰因子(BMF)以及细胞周期蛋白激酶抑制因子p27(p27Kip1)的表达情况。结果:MDA-MB-231/DOX细胞中的miR-221/222表达水平高于亲本MDA-MB-231细胞(P0.05);MDA-MB-231/DOX细胞转染miR-221/222 inhibitor 96 h后,miR-221/222的表达水平低于空白对照组和阴性对照组(P0.05);与空白对照组相比,MDA-MB-231/DOX细胞转染miR-221/222 inhibitor 48h后,DOX继续处理48 h后,细胞的凋亡率明显升高,且细胞内的促凋亡蛋白PUMA,BMF以及p27Kip1的表达均增加(P0.05);DOX对inhibitor组耐药细胞的半数抑制浓度(IC50)显著低于空白对照组细胞及阴性对照组(P0.05)。结论:miR-221/222能够增加MDA-MB-231/DOX细胞对DOX的耐药性,这可能与下调促凋亡蛋白的表达有关;降低miR-221/222水平可诱导MDA-MB-231/DOX凋亡,并且上调促凋亡蛋白的表达,从而部分逆转MDA-MB-231/DOX对DOX的耐药性。     

二甲双胍联合阿霉素应用对人乳腺癌细胞增殖和凋亡的影响

目的：观察二甲双胍联合阿霉素应用对人乳腺癌细胞MDA-MB-231增殖和凋亡的影响。方法：MTT法分别检测二甲双胍、阿霉素和二甲双胍联合阿霉素对MDA-MB-231细胞生长的抑制作用;平板克隆实验检测二甲双胍联合阿霉素对MDA-MB-231细胞克隆形成能力的影响;流式细胞仪检测二甲双胍联合阿霉素对MDA-MB-231细胞凋亡的影响。结果：二甲双胍和阿霉素分别对MDA-MB-231细胞生长有抑制作用,二甲双胍联合阿霉素应用对MDA-MB-231细胞生长的抑制作用更加显著,并且随着药物浓度的增加而增加;二甲双胍联合阿霉素应用与单药相比能够明显降低MDA-MB-231细胞克隆形成率,并且促进细胞凋亡。结论：二甲双胍联合阿霉素应用与单药相比能够显著抑制人乳腺癌细胞MDA-MB-231细胞的增值,促进其凋亡,可见两药联用对肿瘤细胞的杀伤具有协同性。     

粉防己碱逆转阿霉素的人乳腺癌MCF—7细胞的抗凋亡作用

肿瘤细胞的多药耐药性与抗细胞凋亡作用关系密切。本研究用抗肿瘤药物阿霉素 (5μmol· L- 1 )处理人乳腺癌敏感和耐药的 MCF- 7细胞 2 4hr后 ,观察到在敏感细胞中 ,有较多的漂浮细胞 ,阿霉素主要分布在细胞核中 ;而在耐药细胞中 ,细胞形态未发生变化 ,阿霉素主要分布在细胞质中 ,其含量明显减少。阿霉素诱导 MCF- 7细胞的凋亡作用进一步用 An-nexin V - FITC染色法证实。此外 ,用高效逆转耐药性的药物粉防己碱 (2 0μmol· L- 1 )与阿霉素合用处理敏感和耐药的细胞 ,用线粒体荧光染料 Mitosensor TM染色 ,证明合用组凋亡细胞明显增多。通过流式细胞术分析显示 :细胞凋亡的发生与细胞周期无关。本研究表明 :粉防己碱能逆转耐阿霉素的人乳腺癌 MCF- 7细胞的抗凋亡作用。     

敲除Wdr1抑制小鼠原代血管平滑肌细胞的迁移和增殖

细胞骨架肌动蛋白在细胞增殖、迁移等生物学过程中发挥重要作用,然而WDR1作为肌动蛋白解聚的主要辅助因子,其在平滑肌细胞中的作用尚无报道。构建Wdr1条件性诱导敲除小鼠模型,进而分离小鼠原代主动脉平滑肌细胞,诱导敲除Wdr1,检测平滑肌细胞的形态、增殖和迁移情况。PCR结果显示,Wdr1f/f;ERT2Cre小鼠模型构建成功。免疫荧光结果表明:在前人基础上改进的分离方法能够高效分离原代平滑肌细胞。细胞形态观察结果显示:Wdr1敲除后对细胞的形态有显著性影响。同时,划痕实验以及CCK8检测结果也表明:Wdr1的条件性诱导性敲除可明显抑制平滑肌细胞的迁移和增殖。Wdr1敲除后平滑肌细胞的形态以及细胞生物学过程的改变提示其与血管疾病的发生和发展有紧密联系,这对揭示血管病理生理过程有重要意义。     

PTHrP Expression in Human MDA-MB-231 Breast Cancer Cells Is Critical for Tumor Growth and Survival and Osteoblast Inhibition

This study examined the effects of parathyroid hormone-related protein (PTHrP) derived from human MDA-MB-231 breast cancer cells on the tumor growth and osteoblast inhibition. Results revealed that knocking down PTHrP expression in the breast cancer cells strikingly inhibited the formation of subcutaneous tumors in nude mice. PTHrP knockdown dramatically decreased the levels of cyclins D1 and A1 proteins and arrested the cell cycle progression at the G1 stage. PTHrP knockdown led to the cleavage of Caspase 8 and induced apoptosis of the tumor cells. Interestingly, knocking down PTHrP increased the levels of Beclin1 and LC3-II and promoted the formation of autophagosomes. Knocking down PTHrP expression significantly reduced the abilities of the breast cancer cells to inhibit osteoblast differentiation and bone formation in vitro and in vivo. Finally, we found that PTHrP activated its own expression through an autocrine mechanism in MDA-MB-231 cells. Collectively, these studies suggest that targeting PTHrP expression in the tumor cells could be a potential therapeutic strategy for breast cancers, especially those with skeletal metastases.     

亲骨转移乳腺癌细胞MDA-MB-231BO成瘤性的初步研究

目的通过比较亲骨转移乳腺癌细胞（MDA-MB-231BO）和亲代乳腺癌细胞（MDA-MB-231）的生长曲线和致瘤性,初步探讨MDA-MB-231BO细胞的生物学特性。方法MTT法测定两种细胞的生长曲线,并将两种乳腺癌细胞接种于裸鼠腋窝处皮下,建立乳腺癌细胞异种移植瘤动物模型,30 d后处死裸鼠,肿瘤组织及相关脏器官做病理检查。结果MTT法测得MDA-MB-231BO细胞生长速率高于MDA-MB-231细胞。接种两种乳腺癌细胞的裸鼠均长出肿瘤,成瘤率为100%。病理检查符合人乳腺癌细胞特征,MDA-MB-231BO组瘤体体积明显大于MDA-MB-231组（P〈0.05）。结论MDA-MB-231BO细胞生长速率高于MDA-MB-231细胞,而且MDA-MB-231BO在裸鼠体内的致瘤性强于MDA-MB-231。     

Ectophosphatase activity in the triple-negative breast cancer cell line MDA-MB-231

Breast cancer is one of the most common cancers in the female population worldwide, and its development is thought to be associated with genetic mutations that lead to uncontrolled and accelerated growth of breast cells. This abnormal behavior requires extra energy, and indeed, tumor cells display a rewired energy metabolism compared to normal breast cells. Inorganic phosphate (Pi) is a glycolytic substrate of glyceraldehyde-3-phosphate dehydrogenase and has an important role in cancer cell proliferation. For cells to obtain Pi, ectoenzymes in the plasma membrane with their catalytic site facing the extracellular environment can hydrolyze phosphorylated molecules, and this is an initial and possibly limiting step for the uptake of Pi by carriers that behave as adjuvants in the process of energy harvesting and thus partially contributes to tumor energy requirements. In this study, the activity of an ectophosphatase in MDA-MB-231 cells was biochemically characterized, and the results showed that the activity of this enzyme was higher in the acidic pH range and that the enzyme had a K_m = 4.5 ± 0.5 mM para-nitrophenylphosphate and a V_max = 2280 ± 158 nM × h⁻¹ × mg protein⁻¹. In addition, classical acid phosphatase inhibitors, including sodium orthovanadate, decreased enzymatic activity. Sodium orthovanadate was able to inhibit ectophosphatase activity while also inhibiting cell proliferation, adhesion, and migration, which are important processes in tumor progression, especially in metastatic breast cancer MDA-MB-231 cells that have higher ectophosphatase activity than MCF-7 and MCF-10 breast cells.     

SOX7基因启动子甲基化水平对乳腺癌MDA-MB-231细胞株体外迁移和侵袭的影响

目的:探讨乳腺癌MDA-MB-231细胞中,Y性别决定区基因7(SOX7)基因启动子甲基化水平对细胞的体外迁移和侵袭的影响。方法:脂质体转染pcDNA3.0-DNA甲基转移酶3a(DNMT3a)质粒至MDA-MB-231细胞中,并于24h、48h及72h后,采用蛋白质免疫印迹实验(WB)检测细胞内DNMT3a蛋白表达水平;甲基化特异性定量PCR(Q-MSP)检测DNMT3a处理组、5-aza-C处理组及对照(Control)组MDA-MB-231细胞中的SOX7基因启动子DNA甲基化水平;实时荧光定量PCR(qRT-PCR)及WB实验检测各组MDA-MB-231细胞中的SOX7 m RNA和蛋白表达水平;细胞划痕实验及细胞侵袭实验检测各组MDA-MB-231细胞的迁移和侵袭能力。结果:pcDNA3.0-DNMT3a质粒转染MDA-MB-231细胞24h时,细胞内的DNMT3a蛋白表达水平最高。DNMT3a能够显著提高SOX7基因启动子DNA甲基化水平,而5-aza-C则抑制了SOX7基因启动子DNA甲基化水平(P0.05)。与Control组相比,DNMT3a处理组的MDA-MB-231细胞中,SOX7的m RNA及蛋白表达水平均明显下降,而5-aza-C处理组SOX7的m RNA及蛋白表达水平均明显增加(P0.05)。与Control组相比,DNMT3a处理组的MDA-MB-231细胞的迁移和侵袭能力均显著增强(P0.05),而5-aza-C处理组的MDA-MB-231细胞的迁移和侵袭能力变化不大(P0.05)。结论:在恶性肿瘤中,SOX7低表达表受其基因启动子高甲基化调节,且乳腺癌MDA-MB-231细胞中低表达的SOX7能够影响细胞的外迁移和侵袭能力。     

RNA干扰对MDA-MB-231细胞中CaSR基因表达的影响

目的:运用RNA干扰技术,观察siRNA表达载体在乳腺癌细胞MDA-MB-231中对CaSR基因表达的影响。方法:构建靶向CaSR基因的RNA干扰表达载体,用脂质体转染乳腺癌细胞株MDA-MB-231,运用Real-Time荧光定量PCR,Westernblot技术分别从mRNA以及蛋白表达水平检测CaSR基因表达的变化。结果:所构建的质粒载体成功的在MDA-MB-231细胞中抑制了CaSR mRNA及其蛋白的表达。与对照组相比,psiRNA-CaSR载体对CaSR mRNA的抑制率达到65%,对CaSR蛋白抑制率约为70%。结论:实验证明所设计的shRNA片段可以有效地抑制CaSR基因的表达,为下一步研究工作奠定了基础。     

Inhibition of stearoyl-CoA desaturase activity by the cis-9,trans-11 isomer and the trans-10,cis-12 isomer of conjugated linoleic acid in MDA-MB-231 and MCF-7 human breast cancer cells

Conjugated linoleic acid (CLA) is a collective term for a group of positional and geometric conjugated dienoic isomers of linoleic acid. CLA has been shown to have strong inhibitory effects on mammary carcinogenesis both in vitro and in vivo. In this study, we investigated the regulation of human stearoyl-CoA desaturase (SCD, EC 1.14.99.5) expression by CLA in human breast cancer cell lines, MDA-MB-231 and MCF-7. Treatment of the cells with the cis-9,trans-11 and trans-10,cis-12 CLA isomers (45 microM) did not repress SCD mRNA in both MDA-MB-231 and MCF-7 cells. However, the cis-9,trans-11 and trans-10,cis-12 CLA isomers significantly decreased SCD protein levels and SCD activity in MDA-MB-231 cells. In MCF-7 cells, both isomers did not affect protein levels, but they inhibited SCD activity. These results suggest that in MDA-MB-231 cells the cis-9,trans-11 and trans-10,cis-12 CLA isomers regulate human SCD by reducing SCD protein levels, while in MCF-7 cells both isomers have a direct inhibitory effect on SCD enzyme activity.     

Arachidonic acid promotes FAK activation and migration in MDA-MB-231 breast cancer cells

Arachidonic acid (AA) is a common dietary n-6 polyunsaturated fatty acid that is present in an esterified form in cell membrane phospholipids, and it might be present in the extracellular microenvironment. In particular, AA promotes MAPK activation and mediates the adhesion of MDA-MB-435 breast cancer cells to type IV collagen. However, the signal transduction pathways mediated by AA have not been studied in detail. Our results demonstrate that stimulation of MDA-MB-231 breast cancer cells with AA promotes an increase in the phoshorylation of Src and FAK, as revealed by site-specific antibodies that recognized the phosphorylation state of Src at Tyr-418, and of FAK at tyrosine-397 and in vitro kinase assays. In addition, AA also induces an increase in the migration of MDA-MB-231 cells. In contrast, AA does not induce phosphorylation of FAK and an increase in cell migration of non-tumorigenic epithelial cells MCF10A. Inhibition of Gi/Go proteins, LOX and Src activity prevent FAK activation and cell migration. In conclusion, our results demonstrate, for the first time, that Gi/Go proteins, LOX and Src play an important role in FAK activation and cell migration induced by AA in MDA-MB-231 breast cancer cells.